It’s already been a huge year for biotech mergers, we just saw the biggest announcement yet, and the buying might not be over.
On Tuesday, Teva Pharmaceuticals announced an offer to buy Mylan for $82 per share in cash and stock in a deal worth about $40 billion, according to a statement.
Hey, check out all the research scientist jobs. Post your resume today!
